RA Capital Management - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 167 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.3%.

Quarter-by-quarter ownership
RA Capital Management ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q1 2023$62,424,293
-32.5%
1,734,972
-16.4%
1.41%
-24.7%
Q4 2022$92,482,750
+58.6%
2,075,0000.0%1.88%
+50.8%
Q3 2022$58,328,000
+4.3%
2,075,0000.0%1.24%
-16.6%
Q2 2022$55,942,000
-20.8%
2,075,0000.0%1.49%
-3.2%
Q1 2022$70,675,000
+1.3%
2,075,000
+15.0%
1.54%
+25.4%
Q4 2021$69,737,000
-19.3%
1,804,795
+12.8%
1.23%
+2.8%
Q3 2021$86,384,000
+1549.8%
1,600,000
+353.2%
1.20%
+1146.9%
Q3 2020$5,236,000
-65.0%
353,072
-69.3%
0.10%
-67.0%
Q2 2020$14,950,0001,150,0000.29%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q4 2022
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders